Manufactured by:TriBio Science
RUO

ZSTK474, PI 3-Kinase inhibitor

Novel Class I phosphatidylinositol 3-kinase (PI3K) inhibitor. ZSTK474 is an ATP-competitive inhibitor of all four Class I PI3K isoforms. However, it inhibits PI3Kδ most potently, with a Ki of 1.8 nM, while inhibiting the α, β and γ isoforms at slightly higher concentrations (6.7 nM, 10.4 nM and...

SKU:
ABM148984-1
Manufacturer SKU
TBI2180-25MG | TBI2180-5MG
Product type
Biochemical Inhibitors
TargetPI 3-Kinase
Purity>98%

Manufacturer provenance

Manufactured by:
TriBio Science
Sold by:
ABMIUM
Fulfilled from:
Manufacturer facility or confirmed fulfilment location

Know who made it. See the evidence. Buy through one marketplace.

Product description

Novel Class I phosphatidylinositol 3-kinase (PI3K) inhibitor. ZSTK474 is an ATP-competitive inhibitor of all four Class I PI3K isoforms. However, it inhibits PI3Kδ most potently, with a Ki of 1.8 nM, while inhibiting the α, β and γ isoforms at slightly higher concentrations (6.7 nM, 10.4 nM and 11.7 nM, respectively). Displays potent antitumor activity against human cancer xenografts (A549, PC-3 and WiDr) when administered to mice. It displays potent anti-inflammatory activity via modulation of human CD14+ monocyte-derived dendritic cell functions and suppresses experimental autoimmune encephalomyelitis. Ameliorates the progression of adjuvant-induced arthritis in a rat model

Key facts & specifications
Also known as
2-(2-Difluoromethylbenzoimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine
Molecular weight
417.41
Form / buffer
powder
Activity
Novel Class I phosphatidylinositol 3-kinase (PI3K) inhibitor. ZSTK474 is an ATP-competitive inhibitor of all four Class I PI3K isoforms. However, it inhibits PI3Kδ most potently, with a Ki of 1.8 nM, while inhibiting the α, β and γ isoforms at slightly higher concentrations (6.7 nM, 10.4 nM and 11.7 nM, respectively). Displays potent antitumor activity against human cancer xenografts (A549, PC-3 and WiDr) when administered to mice. It displays potent anti-inflammatory activity via modulation of human CD14+ monocyte-derived dendritic cell functions and suppresses experimental autoimmune encephalomyelitis. Ameliorates the progression of adjuvant-induced arthritis in a rat model.
Molecular formula
C 19 H 21 F 2 N 7 O 2
Solubility
Soluble in DMSO (up to 20 mg/ml) or in Ethanol (up to 2.5 mg/ml with warming).
Technical note
Stability: ≥ 2 years.
Identifiers & database references
Manufacturer SKU
TBI2180-25MG | TBI2180-5MG
CAS number
475110-96-4
Storage, stability & shipping
Storage conditions
-20°C
Shipped at
4°C
Long-term storage
-20°C
Compliance & documents
Datasheet
Open datasheet
Safety data sheet
Open SDS
Frequently asked questions
Who manufactured this product?

This product is manufactured by TriBio Science and sold through ABMIUM without relabelling.

Can ABMIUM ship this product internationally?

ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.

Can I check suitability before ordering?

Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.

Is this product for clinical use?

Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.

TriBio Science
£229.00